Frequently Asked Questions
The significant factors flourishing the growth of the Fibromyalgia Market are Increased Incidence of Fibromyalgia, and Rising Demand for Oral Drugs.
The global fibromyalgia market is projected to grow at a CAGR of 7% during the forecast period of 2022-2029.
The major players operating in the Fibromyalgia Market are Pfizer Inc (U.S.), AstraZeneca (U.K.), Johnson and Johnson services Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Janssen Pharmaceuticals, Inc. (Belgium), Sanofi (France), Merck & Co., Inc (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Bristol Myers Squibb Company (U.S.) GlaxoSmithKline Plc. (U.S.), Bayer AG (U.S.), Perrigo Company plc (Ireland), Sun Pharmaceutical Industries Ltd. (India), Cipher Pharmaceuticals Inc. (U.S.), Novartis AG (Switzerland), Eli Lilly & Company (U.S.), and Aurobindo Pharma (India).
The major countries covered in the Fibromyalgia Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
